Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ExonHit and Allergan expand collaboration

This article was originally published in Scrip

Executive Summary

French company ExonHit Therapeutics and Allergan have expanded and extended an agreement to develop drugs for neurodegenerative and eye diseases and pain. Financial details have not been disclosed. Allergan has exercised its option to extend the deal until December 2011 and it now includes the discovery of antibodies for eye disorders based on epitope technology. The agreement expands Allergan's rights to sublicense potential compounds. ExonHit will receive up-front payments and development and sales-based milestones as well as royalties on future sales. EHT/AGN 0001, the most advanced compound from the collaboration, is completing Phase I trials for pain. Other compounds are in preclinical testing for pain, ophthalmology and neurodegenerative disease indications. The companies initiated the deal in December 2002 and have renewed it several times.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC007724

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel